" class="no-js "lang="en-US"> Oxford Science Enterprises Strengthens Investment Teams with Two New Appointments - Medtech Alert
Tuesday, April 23, 2024

Oxford Science Enterprises Strengthens Investment Teams with Two New Appointments

Oxford Science Enterprises, the Science Business Builder and preferred investment partner of the University of Oxford, today announces further strengthening of its investment teams with the appointments of Heather Roxborough PhD as Partner, Health Tech and Wallace Wallace MPhil as Associate, Life Sciences.

As Partner, Heather will lead the Health Tech investment team to identify cutting-edge science and technology from the University’s world leading academics, drive investments into new spinouts and support the scale up of existing enterprises. Wallace joins the growing Life Sciences team to support the creation of new businesses and ongoing work across the current portfolio.

Alexis Dormandy, CEO Oxford Science Enterprises, said: “I am thrilled to welcome Heather and Wallace. Heather brings over 15 years of investment and leadership experience, with a strong track record of deal-making and company building to lead the Health Tech team. While Wallace’s experience in scientific due diligence and early-stage investing strengthens the Life Sciences team. These appointments continue to demonstrate our commitment and enhanced ability to identify, support and commercialise the University of Oxford’s cutting-edge science in order to build world-leading businesses.”

Heather Roxborough PhD, Partner, Health Tech

Heather is a highly experienced venture capitalist, with over 15 years of investment and company building experience from across a range of sectors, including health tech, consumer healthcare, pharmaceuticals, medical devices and food technology.

Heather joins Oxford Science Enterprises from Optum Ventures where she was a Partner, responsible for establishing and leading the global health tech investment fund on behalf of Optum, a leading technology-enabled US health services business, part of UnitedHealth Group.

Heather has also held investment roles at J&J Innovations as Senior Director and Tate and Lyle Ventures as Principal. She holds a PhD in Clinical Biochemistry from Queen’s University of Belfast.

Wallace Wallace MPhil, Associate, Life Sciences

Wallace joins Oxford Science Enterprises from M-Ventures, the corporate venture capital arm of Merck KGaA, where she supported the life sciences investment team across scientific due diligence and portfolio management.

Prior to this, Wallace worked at Accenture as a consultant, assisting the Business Strategy and Operation Strategy units, advising financial services clients.

She holds a BSc in Genetics from the University of York and an MPhil in Bioscience Enterprise from the University of Cambridge.

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more